Sangamo Therapeutics
SGMO
SGMO
193 hedge funds and large institutions have $657M invested in Sangamo Therapeutics in 2019 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 56 increasing their positions, 56 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
12% less capital invested
Capital invested by funds: $744M → $657M (-$87.2M)
21% less call options, than puts
Call options by funds: $10.5M | Put options by funds: $13.4M
Holders
193
Holding in Top 10
–
Calls
$10.5M
Puts
$13.4M
Top Buyers
| 1 | +$5.99M | |
| 2 | +$4.93M | |
| 3 | +$3.35M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$3.17M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$2.83M |
Top Sellers
| 1 | -$26.3M | |
| 2 | -$10.2M | |
| 3 | -$8.39M | |
| 4 |
Jennison Associates
New York
|
-$4.67M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.53M |